News

As sales slump, new Intel CEO's contract manufacturing plan to face investor scrutiny
Intel is set to report its sixth consecutive net loss on July 24, while revenue is expected to drop for a fifth straight ...
Fierce Pharma8h
CDMO pulse check: Lonza posts major sales rebound as Samsung Bio keeps revenue growth rolling
For many contract manufacturers, the end of the COVID-19 pandemic—and the production contracts that came with it—marked a ...
Bio/Pharmaceutical Outsourcing Report, May 2025 Edition - Discover the Latest Outsourcing Contracts, Opportunities, Threats, Mergers, and Investments
Get insights from the Bio/Pharmaceutical Outsourcing Report, a comprehensive monthly analysis of trends and news impacting pharmaceutical CMOs.. Essential for CMO execs, procurement leaders, investors ...
Pharmabiz15h
WuXi Biologics secures US FDA Pre-License Inspection approval for five facilities, first for commercial PFS line
WuXi Biologics secures US FDA Pre-License Inspection approval for five facilities, first for commercial PFS line: Wuxi, China Wednesday, July 23, 2025, 13:00 Hrs [IST] WuXi Biolog ...
The Manila Times15h
Samsung Biologics reports second quarter 2025 financial results
Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion Recorded Q2'25 consolidated operating profit of KRW 475.6 billion ...